Aetna modified CPB 0774 covering intra-epidermal nerve fiber density (IENFD) measurement by skin biopsy, effective December 12, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its nerve fiber density measurement coverage policy under CPB 0774 in the Aetna system. The policy narrows medical necessity approval to a specific four-part clinical criteria set — and designates a growing list of indications as experimental or investigational, including fibromyalgia, Fabry disease, and Ehlers-Danlos syndromes. If your team bills CPT 11104, 88305, or 88356 for skin biopsy and nerve morphometry in small-fiber neuropathy workups, this policy change directly affects your reimbursement.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Nerve Fiber Density Measurement |
| Policy Code | CPB 0774 |
| Change Type | Modified |
| Effective Date | December 12, 2025 |
| Impact Level | High |
| Specialties Affected | Neurology, Pain Management, Pathology, Clinical Lab |
| Key Action | Audit all IENFD claims against four-part medical necessity criteria before billing after December 12, 2025 |
Aetna Nerve Fiber Density Coverage Criteria and Medical Necessity Requirements 2025
The Aetna nerve fiber density coverage policy under CPB 0774 covers IENFD measurement by skin biopsy for small-fiber neuropathy diagnosis — but only when all four criteria below are met. Miss one, and the claim is experimental by default.
All four criteria must apply:
| # | Covered Indication |
|---|---|
| 1 | The patient presents with painful sensory neuropathy. |
| 2 | There is no history of a disorder known to predispose to painful neuropathy — this includes diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, and inherited neuropathy. |
| 3 | Physical exam shows no signs of large-fiber neuropathy, such as reduced or absent muscle-stretch reflexes, or reduced proprioception and vibration sensation. |
| 4 | Needle EMG (CPT 95860–95872) and nerve conduction studies (CPT 95907–95913) are normal, showing no evidence of large-fiber neuropathy. |
This is a "rule-out everything else first" structure. IENFD via skin biopsy — billed through CPT 11104 for the punch biopsy and 88305 for gross and microscopic pathology examination — is reserved for cases where standard neurological workup draws a blank.
The real issue here is criterion two. If a patient has any known predisposing condition — diabetes is the obvious one — Aetna will not cover IENFD under this policy. That rules out the majority of neuropathy patients in most practices. If you see high volumes of diabetic neuropathy cases, expect most IENFD claims to land in experimental territory under Aetna billing guidelines.
Prior authorization requirements are not explicitly outlined in CPB 0774 itself. That said, the criteria structure signals that Aetna will scrutinize these claims heavily at the clinical review level. Talk to your compliance officer if your team bills IENFD regularly — documentation supporting all four criteria needs to be airtight before the claim goes out.
Aetna Nerve Fiber Density Exclusions and Non-Covered Indications 2025
Aetna designates IENFD measurement as experimental, investigational, or unproven for a long list of indications. This list expanded with the December 12, 2025 update — and the additions signal that Aetna is drawing a harder line on off-label uses.
Aetna considers IENFD experimental for all of the following:
| # | Excluded Procedure |
|---|---|
| 1 | Monitoring disease progression or treatment response — even in covered diagnoses |
| 2 | Pre-clinical asymptomatic small-fiber sensory neuropathy screening in hypothyroid patients |
| 3 | Diagnosis of endometriosis |
| 4 | Evaluation of hereditary or iatrogenic transthyretin (TTR) amyloidosis |
| 5 | Evaluation of Ehlers-Danlos syndromes |
| 6 | Evaluation of Fabry disease |
| 7 | Evaluation of fibromyalgia |
| 8 | Evaluation of postural tachycardia syndrome (POTS) |
| 9 | Evaluation of REM sleep behavior disorder |
That last point about treatment monitoring is worth flagging separately. Even if a patient qualifies under the four-part criteria for an initial diagnosis, using IENFD to monitor how they're responding to treatment is not covered. You can bill the initial diagnostic workup. You cannot bill serial skin biopsies to track nerve fiber recovery.
Aetna also designates sweat gland nerve fiber density measurement as experimental across all indications — including complex regional pain syndrome (CRPS) and small-fiber neuropathy. This is distinct from intra-epidermal nerve fiber density. If your neurologist is ordering sweat gland testing, there is no covered pathway under CPB 0774.
For autonomic testing related to these conditions, see Aetna CPB 0485, which covers sudomotor and autonomic testing. Billing the wrong policy will get you a claim denial. Route sweat gland and autonomic workups there, not here.
Coverage Indications at a Glance
| Indication | Coverage Status | Relevant CPT Codes | Notes |
|---|---|---|---|
| Small-fiber neuropathy diagnosis (all 4 criteria met) | Covered | 11104, 11105, 88305, 88314, 88341–88344, 88356 | Requires normal EMG and NCS; no predisposing condition |
| Small-fiber neuropathy — monitoring or treatment response | Experimental | 11104, 88305, 88356 | Not covered even in confirmed SFN cases |
| Diabetic neuropathy evaluation | Not Covered | — | Known predisposing condition; excluded by criterion 2 |
| HIV neuropathy evaluation | Not Covered | — | Known predisposing condition; excluded by criterion 2 |
| Toxic or celiac neuropathy evaluation | Not Covered | — | Known predisposing condition; excluded by criterion 2 |
| Inherited neuropathy evaluation | Not Covered | — | Known predisposing condition; excluded by criterion 2 |
| Fibromyalgia evaluation | Experimental | — | Explicitly listed as unproven |
| Postural tachycardia syndrome (POTS) | Experimental | — | Explicitly listed as unproven |
| Fabry disease evaluation | Experimental | — | Explicitly listed as unproven |
| Ehlers-Danlos syndromes evaluation | Experimental | — | Explicitly listed as unproven |
| TTR amyloidosis (hereditary or iatrogenic) | Experimental | — | Explicitly listed as unproven |
| Endometriosis diagnosis | Experimental | — | Explicitly listed as unproven |
| REM sleep behavior disorder evaluation | Experimental | — | Explicitly listed as unproven |
| Hypothyroid pre-clinical screening | Experimental | — | Explicitly listed as unproven |
| Sweat gland nerve fiber density — any indication | Experimental | — | Includes CRPS and SFN; see CPB 0485 for autonomic testing |
Aetna Nerve Fiber Density Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your current IENFD claims before December 12, 2025. Pull all open or pending claims that include CPT 11104, 88305, 88356, or the immunohistochemistry codes 88341–88344. Verify each against the four-part criteria. If a claim doesn't satisfy all four, hold it and review with your billing team. |
| 2 | Update your charge capture to flag cases with predisposing conditions. Build a hard stop in your workflow for any IENFD order tied to a diabetic neuropathy ICD-10 (E08.40–E13.49 range) or HIV, toxic, or inherited neuropathy diagnosis. These cases do not qualify under this coverage policy. |
| 3 | Document EMG and NCS results in every IENFD claim. CPT codes 95860–95872 for EMG and 95907–95913 for nerve conduction studies must be on record and show normal results before IENFD billing is defensible. If those results aren't in the chart, the skin biopsy claim has no foundation under CPB 0774. |
| 4 | Stop billing serial IENFD for treatment monitoring. This is now explicitly experimental. If your neurologists order follow-up skin biopsies to track treatment response, those claims will be denied. Have a conversation with your ordering providers about the coverage wall before the order goes in. |
| 5 | Separate sweat gland nerve fiber density from IENFD in your workflows. They are not the same test, and they live under different policies. Sweat gland testing for CRPS or small-fiber neuropathy is not covered under CPB 0774. Route those to CPB 0485 for autonomic testing evaluation. |
| 6 | Brief your neurology and pathology teams on the expanded experimental list. Fibromyalgia, POTS, Fabry disease, Ehlers-Danlos, and TTR amyloidosis patients are now explicitly called out. If your practice sees high volumes of any of these diagnoses, the ordering provider needs to know the coverage wall before they send the order to the lab. |
| 7 | Talk to your compliance officer if IENFD billing is high-volume for your group. The criteria are narrow, the exclusions are long, and Aetna nerve fiber density billing under this policy has real claim denial exposure for groups that haven't audited their documentation. The effective date is December 12, 2025 — that doesn't give you much runway. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Nerve Fiber Density Measurement Under CPB 0774
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 11104 | CPT | Punch biopsy of skin (including simple closure, when performed); single lesion |
| 11105 | CPT | Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion |
| 88305 | CPT | Level IV Surgical pathology, gross and microscopic examination, nerve, biopsy |
| +88314 | CPT | Special stain including interpretation and report; histochemical stain on frozen tissue block |
| 88341 | CPT | Immunohistochemistry or immunocytochemistry, per specimen |
| 88342 | CPT | Immunohistochemistry or immunocytochemistry, per specimen |
| 88343 | CPT | Immunohistochemistry or immunocytochemistry, per specimen |
| 88344 | CPT | Immunohistochemistry or immunocytochemistry, per specimen |
| 88356 | CPT | Morphometric analysis; nerve |
Prerequisite Testing CPT Codes (Required for Medical Necessity Documentation)
These codes support the required normal EMG and nerve conduction study results. They are not themselves covered under CPB 0774 — they are prerequisite documentation.
| Code | Type | Description |
|---|---|---|
| 95860 | CPT | Electromyography |
| 95861 | CPT | Electromyography |
| 95862 | CPT | Electromyography |
| 95863 | CPT | Electromyography |
| 95864 | CPT | Electromyography |
| 95865 | CPT | Electromyography |
| 95866 | CPT | Electromyography |
| 95867 | CPT | Electromyography |
| 95868 | CPT | Electromyography |
| 95869 | CPT | Electromyography |
| 95870 | CPT | Electromyography |
| 95871 | CPT | Electromyography |
| 95872 | CPT | Electromyography |
| 95907 | CPT | Nerve conduction studies |
| 95908 | CPT | Nerve conduction studies |
| 95909 | CPT | Nerve conduction studies |
| 95910 | CPT | Nerve conduction studies |
| 95911 | CPT | Nerve conduction studies |
| 95912 | CPT | Nerve conduction studies |
| 95913 | CPT | Nerve conduction studies |
| 95921 | CPT | Testing of autonomic nervous system function |
| 95922 | CPT | Testing of autonomic nervous system function |
| 95923 | CPT | Testing of autonomic nervous system function |
| 95937 | CPT | Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method |
| 10004 | CPT | Fine needle aspiration biopsy, without imaging guidance; each additional lesion |
Key ICD-10-CM Diagnosis Codes
The ICD-10 codes listed in CPB 0774 are largely associated with conditions that exclude coverage — particularly diabetic neuropathy diagnoses that trigger criterion two of the medical necessity exclusion.
| Code Range | Description |
|---|---|
| E00.0–E00.9 | Congenital iodine-deficiency syndrome (hypothyroid pre-clinical screening — experimental) |
| E03.0–E03.1 | Other hypothyroidism (hypothyroid pre-clinical screening — experimental) |
| E08.40–E08.49 | Diabetes mellitus due to underlying condition with neurological complications — excludes coverage |
| E09.40–E09.49 | Drug or chemical induced diabetes mellitus with neurological complications — excludes coverage |
| E10.40–E10.49 | Type 1 diabetes mellitus with neurological complications — excludes coverage |
| E11.40–E11.49 | Type 2 diabetes mellitus with neurological complications — excludes coverage |
| E13.40–E13.49 | Other specified diabetes mellitus with neurological complications — excludes coverage |
When any of these codes appear in the patient record, IENFD measurement will not meet the four-part criteria for coverage under CPB 0774. If your billing team sees these codes attached to an IENFD claim, that is a claim denial waiting to happen.
Get the Full Picture for CPT 11104
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.